AskBio France, SAS, a subsidiary of AskBio Inc.

Clinical trials sponsored by AskBio France, SAS, a subsidiary of AskBio Inc., explained in plain language.

Now part of Bayer AG BAYN XETRA

A subsidiary of AskBio, a gene therapy company owned by Bayer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

Brain injection aims to slow Huntington's

Disease control Ongoing

This early-stage study tests a gene therapy called AB-1001 in 5 adults with early Huntington's disease. The treatment is injected directly into the brain to potentially slow the disease. The main goal is to check safety, but researchers will also look at brain changes on MRI and …

Phase 1/2 • Sponsor: AskBio France, SAS, a subsidiary of AskBio Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

AskBio France, SAS, a subsidiary of AskBio Inc.

Brain injection aims to slow Huntington's